Avalo Therapeutics (AVTX) Invested Capital (2014 - 2025)

Avalo Therapeutics (AVTX) has 6 years of Invested Capital data on file, last reported at $1.2 million in Q3 2019.

• Quarterly Invested Capital fell 36.8% year-over-year to $1.2 million in Q3 2019, while the trailing twelve-month figure through Jun 2020 was $1.2 million (down 81.12% YoY) and the FY2018 annual result came in at $859670.0, changed N/A from the prior year.
• Invested Capital retreated to $1.2 million in Q3 2019, from $1.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $3.4 million in Q2 2016 to a low of $607598.0 in Q2 2017.
• A 5-year average of $2.0 million and a median of $2.0 million in 2018 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2017 — Invested Capital plunged 82.08% — and 2019, when it surged 165.98%.
• Tracing AVTX's Invested Capital over 5 years: stood at $3.2 million in 2015, then decreased by 26.63% to $2.4 million in 2016, then slumped by 74.19% to $607598.0 in 2017, then jumped by 41.49% to $859670.0 in 2018, then surged by 43.94% to $1.2 million in 2019.
• The last three Invested Capital figures came in at $1.2 million (Q3 2019), $1.5 million (Q2 2019), and $2.2 million (Q1 2019), per Business Quant data.